Showing results (361-370 of 427) with videos related to

Sort By:
Pageof 43
Journal of Hepatology|December 21, 2024
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinomaSarah Cappuyns, Marta Piqué-Gili, Roger Esteban-Fabró, et al.
Journal for Immunotherapy of Cancer|November 30, 2022
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registriesAlessio Cortellini, Gino M Dettorre, Urania Dafni, et al.
Therapeutic Advances in Medical Oncology|January 22, 2024
Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registryBruno Vincenzi, Alessio Cortellini, Alessandro Mazzocca, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 26, 2026
Predicting decompensation in unresectable hepatocellular carcinoma on atezolizumab plus bevacizumab: the ARTE ScoreLorenzo Canova, Eleonora Alimenti, Lorenzo Argiento, et al.
JHEP Reports : Innovation in Hepatology|December 29, 2022
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinomaBernhard Scheiner, Daniel Roessler, Samuel Phen, et al.
Cell Reports. Medicine|April 1, 2025
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Mikael H Sodergren, Rose Hodgson, et al.
Journal of Hepatocellular Carcinoma|April 9, 2025
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and BevacizumabBernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, et al.
Science Translational Medicine|July 15, 2021
Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancerStelios Chrysostomou, Rajat Roy, Filippo Prischi, et al.
JHEP Reports : Innovation in Hepatology|February 12, 2026
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real studyCiro Celsa, Tiziana Pressiani, Naoshi Nishida, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 29, 2023
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registryAnahita Mostaghim, Samuel Minkove, Juan Aguilar-Company, et al.
Pageof 43